Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Northeast Pharmaceutical Group To Give Up Stake In ShenYang TCM Pharmaceutical

This article was originally published in PharmAsia News

Executive Summary

The Shenyang Property Rights Transaction Center's information shows that Northeast Pharmaceutical Group plans to transfer its 20 percent stake in ShenYang TCM Pharmaceutical at a price of RMB 35 million ($5.1 million). ShenYang TCM Pharmaceutical, a Sino-British joint venture, is one of China's key TCM pharmaceutical companies. It mainly engages in Chinese patent medicine R&D, processing and manufacturing; TCM extraction; herbal medicine processing; as well as medicinal raw material purchasing. The firm's major product Shenyang Hongyao has become a renowned brand in the nation's TCM industry. A manager of the transaction reveals that Northeast Pharmaceutical Group's move stems from investment restructuring, which will focus the development of its core chemical medicine business. (Click here for more - Chinese Language)

You may also be interested in...

Amgen Settles On Bevacizumab And Trastuzumab

Amgen has filed to settle on undisclosed terms patent-infringement litigation involving both its Kanjinti and Mvasi biosimilars, having previously seen originator Genentech fail multiple times to block commercial sales of the products that were launched ‘at risk’.

WHO Stops Clinical Trials Involving Hydroxychloroquine And HIV Drugs

The WHO’s “Solidarity” trial investigators have decided to interrupt the trials with immediate effect since the clinical trial found that hydroxychloroquine and lopinavir/ritonavir “produced little or no reduction in the mortality of the hospitalized COVID-19 patients.”

Caplin Partners With Xellia For Five Injectables

With a pipeline of over 35 ANDAs, India's Caplin Steriles plans to launch five generic injectables through a strategic partnership with Xellia Pharma in the US market. Out of the five ANDAs, one has been approved and is ready for launch.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts